Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer: Clinical trial finds 60.9% overall response rate (ORR) with combination of encorafenib, cetuximab and mFOLFOX6 compared to 40% with standard-of-care (SOC) treatment.
Read Full Article
#BRAFmutated #ColorectalCancer #TargetedTherapy #ClinicalTrial #CancerResearch
Read Full Article
#BRAFmutated #ColorectalCancer #TargetedTherapy #ClinicalTrial #CancerResearch
EurekAlert!
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER…
👏1